Saturday, September 6, 2025
  • Login
Forbes 40under40
  • Home
  • Technology
  • Innovation
  • Real Estate
  • Leadership
  • Money
  • Lifestyle
No Result
View All Result
  • Home
  • Technology
  • Innovation
  • Real Estate
  • Leadership
  • Money
  • Lifestyle
No Result
View All Result
Forbes 40under40
No Result
View All Result
Home Leadership

Merck snags Chinese cancer drug for up to US$3.3 billion

by Yurie Miyazawa
in Leadership
Merck snags Chinese cancer drug for up to US.3 billion
Share on FacebookShare on Twitter


MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million upfront, plus as much as US$2.7 billion in milestone payments.

The deal with LaNova Medicines bolsters Merck’s push into the promising new field of dual-targeted antibodies. Under the agreement, it will gain exclusive global rights to LM-299, a so-called bispecific antibody that hits cancer in multiple ways.

The drug is currently in a phase one trial in China, where LaNova Medicines is based. In a statement, Dean Li, president of Merck Research Laboratories, said the company plans to advance the drug “with speed and rigor for patients in need.”

LM-299 activates the immune system to fight cancer by blocking a protein called PD-1, the same one targeted by Merck’s best-selling cancer drug Keytruda. But it also blocks a protein called VEGF that tumors use to spur the growth of the blood vessels that support them. This second mechanism is similar to the way Roche Holding AG’s cancer drug Avastin works.

Merck shares rose as much as 0.7 per cent on Thursday (Nov 14) before US markets opened, and have lost 9.7 per cent this year through Wednesday’s close.

In recent years, Merck has spent heavily to broaden its portfolio and reduce its dependence on Keytruda. In 2023, the company paid almost US$11 billion to acquire Prometheus Biosciences, which makes treatments for autoimmune disorders, and signed a cancer drug collaboration with Daiichi Sankyo worth as much as US$22 billion. That followed its US$11 billion purchase of Acceleron Pharma in 2021, which brought in a drug for a rare lung disorder.

Deal demand

But the doubled-barreled cancer medicines called bispecific antibodies have become a red hot area of drug development. Merck itself acquired one such drug for blood cancer in August, buying the global rights to CN201 from closely held Curon Biopharmaceutical for US$700 million in cash plus milestone payments.

In September, shares of Summit Therapeutics soared after researchers presented results showing its dual-targeted drug worked better than Keytruda in a mid-stage lung cancer trial. And in late October, former Seagen chief executive officer David Epstein launched a new company, Ottimo Pharma, to pursue the two pronged approach. The company hasn’t yet started patient trials.

Merck said it expects the deal to close in the fourth quarter, leading it to take a pretax charge related to the US$588 million upfront payment to LaNova. BLOOMBERG

Tags: BillioncancerChineseDrugMercksnagsUS3.3
Yurie Miyazawa

Yurie Miyazawa

Next Post
Offer for Broadway Industrial Group turns unconditional

Offer for Broadway Industrial Group turns unconditional

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Forbes 40under40 stands as a distinguished platform revered for its commitment to honoring and applauding the remarkable achievements of exceptional individuals who have yet to reach the age of 40. This esteemed initiative serves as a beacon of inspiration, spotlighting trailblazers across various industries and domains, showcasing their innovation, leadership, and impact on a global scale.

 
 
 
 

NEWS

  • Forbes Magazine
  • Technology
  • Innovation
  • Money
  • Leadership
  • Real Estate
  • Lifestyle
Instagram Facebook Youtube

© 2025 Forbes 40under40. All Rights Reserved.

  • About Us
  • Advertise
  • Contact Us
No Result
View All Result
  • Home
  • Technology
  • Innovation
  • Real Estate
  • Leadership
  • Money
  • Lifestyle

© 2024 Forbes 40under40. All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In